Omalizumab for the treatment of chronic spontaneous urticaria: AÂ meta-analysis of randomized clinical trials

This meta-analysis provides high-quality evidence for the efficacy and safety of omalizumab in patients with CSU and for treating these patients with 300 mg of omalizumab every 4 weeks.